<p>New Delhi: The World Health Organization has updated its guidelines on treatments for patients with Covid-19, providing latest, trustworthy advice on the management of the disease to help doctors make better decisions.</p>.<p> The new recommendations published by The BMJ are part of a living guideline, developed by the WHO with the methodological support of Norwegian non-profit MAGIC Evidence Ecosystem Foundation.</p>.<p> The guidelines incorporate the latest clinical trial evidence for existing and new Covid-19 therapies and take account of evidence relating to safety, prognosis, resources, access, and equity issues, as well as patient values and preferences, the WHO said.</p>.ICMR study finds past Covid-19 infection as risk factor in sudden deaths in young Indians.<p> The update includes distinct risk categories to help doctors more accurately assess whether an individual is at high, moderate, or low risk of hospital admission and tailor treatment accordingly.</p>.<p> WHO in the update recommends the use of antiviral drug nirmatrelvir-ritonavir in patients with non-severe Covid-19 at high and moderate risk of hospital admission.</p>.<p> It also recommends against the use of the antiviral drugs remdesivir and molnupiravir for patients with non-severe Covid-19 at moderate and low risk of hospital admission (treatment is suggested for patients at high risk of admission).</p>.<p> The update also recommends against the use of a new antiviral (VV116) for patients with Covid-19 except in clinical trials, regardless of illness severity.</p>.<p> The WHO strongly recommends against the use of ivermectin for patients with non-severe Covid-19.</p>.<p> The experts say the new recommendations reflect changes in the virulence and transmissibility of circulating SARS-CoV-2 variants and sub-variants, along with changes in immunity related to global vaccinations.</p>.<p> These changes have led to lower baseline risks of severe illness and death for most patients with non-severe Covid-19, they said. </p>
<p>New Delhi: The World Health Organization has updated its guidelines on treatments for patients with Covid-19, providing latest, trustworthy advice on the management of the disease to help doctors make better decisions.</p>.<p> The new recommendations published by The BMJ are part of a living guideline, developed by the WHO with the methodological support of Norwegian non-profit MAGIC Evidence Ecosystem Foundation.</p>.<p> The guidelines incorporate the latest clinical trial evidence for existing and new Covid-19 therapies and take account of evidence relating to safety, prognosis, resources, access, and equity issues, as well as patient values and preferences, the WHO said.</p>.ICMR study finds past Covid-19 infection as risk factor in sudden deaths in young Indians.<p> The update includes distinct risk categories to help doctors more accurately assess whether an individual is at high, moderate, or low risk of hospital admission and tailor treatment accordingly.</p>.<p> WHO in the update recommends the use of antiviral drug nirmatrelvir-ritonavir in patients with non-severe Covid-19 at high and moderate risk of hospital admission.</p>.<p> It also recommends against the use of the antiviral drugs remdesivir and molnupiravir for patients with non-severe Covid-19 at moderate and low risk of hospital admission (treatment is suggested for patients at high risk of admission).</p>.<p> The update also recommends against the use of a new antiviral (VV116) for patients with Covid-19 except in clinical trials, regardless of illness severity.</p>.<p> The WHO strongly recommends against the use of ivermectin for patients with non-severe Covid-19.</p>.<p> The experts say the new recommendations reflect changes in the virulence and transmissibility of circulating SARS-CoV-2 variants and sub-variants, along with changes in immunity related to global vaccinations.</p>.<p> These changes have led to lower baseline risks of severe illness and death for most patients with non-severe Covid-19, they said. </p>